| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2030445 | Translational Proteomics | 2015 | 9 Pages |
•Analysis of the plasma proteome is still a major analytical challenge.•Few biomarker has been established by proteomics technologies during the last decade.•Better study designs and proteomic technologies will produce multi-panel markers for CVD.
There is an unmet need for new cardiovascular biomarkers. Despite this only few biomarkers for the diagnosis or screening of cardiovascular diseases have been implemented in the clinic. Thousands of proteins can be analysed in plasma by mass spectrometry-based proteomics technologies. Therefore, this technology may therefore identify new biomarkers that previously have not been associated with cardiovascular diseases. In this review, we summarize the key challenges and considerations, including strategies, recent discoveries and clinical applications in cardiovascular proteomics that may lead to the discovery of novel cardiovascular biomarkers.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
